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In Brief
Irisin is an exercise-inducedmyokine with
beneficial metabolic functions. Its
detection in human plasma has, however,
been problematic. Here, Jedrychowski et
al. use state-of-the-art quantitative mass
spectrometry to precisely detect and
quantify circulating irisin and show that it
goes up in individuals undergoing aerobic
interval training.
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Exercise provides many health benefits, including
improved metabolism, cardiovascular health, and
cognition. We have shown previously that FNDC5, a
type I transmembrane protein, and its circulating
form, irisin, convey some of these benefits in mice.
However, recent reports questioned the existence
of circulating human irisin both because human
FNDC5 has a non-canonical ATA translation start
and because of claims that many human irisin anti-
bodies used in commercial ELISA kits lack required
specificity. In this paper we have identified and
quantitated human irisin in plasma using mass spec-
trometry with control peptides enriched with heavy
stable isotopes as internal standards. This precise
state-of-the-art method shows that human irisin is
mainly translated from its non-canonical start codon
and circulates at3.6 ng/ml in sedentary individuals;
this level is increased to 4.3 ng/ml in individuals
undergoing aerobic interval training. These data
unequivocally demonstrate that human irisin exists,
circulates, and is regulated by exercise.
INTRODUCTION
The health benefits of physical activity and exercise are well
recognized (Hawley et al., 2014; Mann and Rosenzweig, 2012;
Voss et al., 2013). Exercise is the first line of therapy for various
metabolic diseases like diabetes and obesity, but exercise also
improves outcomes in diseases involving other tissues, such
as the heart and brain. We recently described a novel polypep-
tide that is secreted from skeletal muscle and is increased with
exercise. Irisin is the shed extracellular domain of a transmem-
brane protein called FNDC5. FNDC5, when expressed from
adenoviral vectors in mice, causes an elevation of irisin in the
blood and improved metabolic health in recipient animals (Bos-
trom et al., 2012). It also stimulates the expression of a potential
neuroprotective gene program in the brain, particularly in the
hippocampus (Wrann et al., 2013). Several papers have studied
the effects of exercise on circulating irisin in humans; positive734 Cell Metabolism 22, 734–740, October 6, 2015 ª2015 Elsevier Inassociations between irisin plasma level and exercise have
been observed in some but not all cohorts and modes of exer-
cise (Daskalopoulou et al., 2014; Hofmann et al., 2014; Huh
et al., 2014; Kraemer et al., 2014; Lee et al., 2014; Norheim
et al., 2014). Data suggest that early sampling after exercise
and high-intensity training protocols are particularly effective at
raising circulating irisin levels. Most of these studies have relied
on commercial antibodies and ELISA assays.
Human FNDC5 has an atypical translation start codon, ATA, in
place of the more typical ATG. While it is now known that many
eukaryotic mRNAs begin translation with non-ATG start codons
(Ingolia et al., 2011; Ivanov et al., 2011; Peabody, 1989), two
recent papers have claimed that this ATA codon in human
FNDC5 represents a null mutation and therefore human irisin
would not be produced (Albrecht et al., 2015; Raschke et al.,
2013). These authors argue that if FNDC5 exists in humans,
it is translated from a downstream ATG, and hence the irisin
polypeptide is a ‘‘myth’’ and does not exist. In addition, these au-
thors claim that the many papers measuring human irisin are all
artifacts of poor antibody specificity (Albrecht et al., 2015; Erick-
son, 2013); this is despite the fact that Lee et al. had previously
detected an irisin peptide in human plasmawithmass spectrom-
etry (Lee et al., 2014). In this paper we have investigated the
presence of human irisin in blood using quantitative mass spec-
trometry. As internal standards, we synthesized irisin peptides
and included a valine enriched in stable isotopes (six 13C atoms).
The peptides were used to develop a quantitative platform for
the measurement of human irisin; these data should facilitate
future studies of this molecule in both mice and humans.
RESULTS
Two peptides were chosen as standards for this mass spectro-
metric analysis. These were both chosen because they are
unique to the irisin sequence (FNDC5 ectodomain) and not en-
coded in any other proteins in the annotated human genome.
As shown in Figure 1A, one peptide represents themost extreme
N-terminal 12 amino acids (DSPSAPVNVTVR12) of the pro-
cessed irisin molecule, coming immediately after the signal pep-
tide (Figure 1A). Importantly, this peptide is downstream of the
non-canonical ATA codon but upstream of the first ATG codon
in the FNDC5 mRNA. Therefore detection of this peptide would
demonstrate use of the non-canonical start codon. A second
tryptic peptide (48FIQEVNTTTR57) was chosen from the centralc.
Figure 1. Analysis of Irisin Peptides by Mass Spectrometry
(A) Schematic representation of the FNDC5 protein structure (top) and irisin (bottom). SP, signal peptide; H, hydrophobic domain; C, C-terminal domain. Below
is shown the human FNDC5 sequence with corresponding domains colored. Human irisin sequence is underlined as are synthetic AQUA peptides used in this
study (red).
(B) Immunoblotting of irisin plasma samples from three subjects undergoing aerobic interval training with or without deglycosylation enzyme (Protein Degly-
cosylation Mix [NEB]) and deglycosylated recombinant irisin.
(C) MS2 spectra acquired using a Q Exactive mass spectrometer for the two synthetic AQUA peptides and their b-, y-ion seriesm/z values. Mass accuracy values
are given in PPMs and ‘‘#’’ denotes the heavy valine residue.
(D) PRM elution profile for the y-ions for the AQUA peptides using Skyline software. Retention times for each peptide are labeled on the x axis, and y axis
represents the relative intensity for each y-ion peak. See also Figure S1.portion of irisin, three amino acids downstream of the ATG.
Plasma samples from human volunteers who had undergone
aerobic interval training (see Experimental Procedures) were
used to develop this assay. These plasma samples were first
treated with a commercial affinity resin to remove the very abun-
dant albumin and immunoglobulins, so that these proteins would
not hinder analysis of less abundant proteins (see Experimental
Procedures). Samples were then deglycosylated with the Pro-
tein Deglycosylation Mix from New England Biolabs (NEB),
which contains PNGase F, O-glycosidase, neuraminidase, b1-
4-galactosidase, and b-N-acetylglucosaminidase and results in
complete deglycosylation. After electrophoresis, the anti-irisinCellantibody detected a band running at 12 kDa, the predicted
size of the irisin polypeptide (Figure 1B). To characterize the syn-
thetic heavy irisin, peptides were subjected to liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) analysis in both
data-dependent and parallel reaction monitoring (PRM) acquisi-
tion modes. As shown in Figure 1C, the intensity of the y ions
series from the MS2 spectra for both peptides corresponds to
the rank order elution profile in the PRM acquisition mode (Fig-
ure 1D), validating that these ions can be used for identification
and quantification of irisin.
Next, for the quantification of irisin in human plasma by mass
spectrometry, albumin- and immunoglobulin-depleted plasmaMetabolism 22, 734–740, October 6, 2015 ª2015 Elsevier Inc. 735
Figure 2. Detection of Irisin in Human Plasma
(A) SDS-PAGE separation of 50 mg of plasma from each subject and visualized by Coomassie staining. Molecular mass regions corresponding to completely
deglycosylated irisin (10–15 kDa) were excised from six separate gels (300 mg from the original 100 ml plasma) for each subject and digested in-gel in the presence
of 12.5 femtomoles of each internal standard AQUA peptide.
(B) PRM elution profile for internal tryptic irisin peptide (FIQEVNTTR) using Skyline software found in sedentary subject 1. Top panel is the deamidated asparagine
form of the peptide found in the plasma, middle panel is the unmodified peptide found in the plasma, and the bottom panel is 12.5 femtomoles of heavy internal
standard (IS) AQUA peptide.
(C) Irisin levels in plasma from sedentary subjects (Sedentary) or subjects undergoing aerobic interval training (Aerobic). Values are shown as mean ± SEM; n = 4
(Sedentary) and n = 6 (Aerobic). *p = 0.0411 compared to sedentary subject group as determined by unpaired t test, two-tailed.
(D) Depicted are several plasma proteins and their circulating concentrations ranging from the mg/ml (red), ng/ml (yellow), and pg/ml (blue) levels. We quantify
circulating plasma irisin at a 3–5 ng/ml. See also Figure S2.from four sedentary and six aerobically interval-trained subjects
was deglycosylated and resolved by SDS-PAGE prior to in-gel
trypsin digestion. After this, 12.5 femtomoles of each heavy pep-
tide were spiked into the sample prior to absolute quantification
(AQUA) of irisin (Figure 2A) (Gerber et al., 2003). Of note, often
with enzymatic deglycosylation of proteins there is a propensity
for deamidation occurring on asparagine residues, increasing
the mass of the residue by 0.984 Da and slightly delaying the
reverse phase retention (Zielinska et al., 2010). Therefore, suc-
cessful identification of human irisin peptides (as for other N-gly-
cosylated plasma proteins) must take into account this mass
shift. Deamidation modifications for both endogenous plasma
irisin peptides are observed without dramatically changing the
MS2 spectra (Figure S1A) nor altering the PRM rank order elution
profile (Figure 2B). Fragment ions for both peptides were quan-736 Cell Metabolism 22, 734–740, October 6, 2015 ª2015 Elsevier Intified using Skyline version 3.1 (MacLean et al., 2010), and
comparable levels of quantification for both peptides, down-
stream of the ATA start codon and the later ATG, suggest irisin
is mainly translated from its non-canonical start codon (Table 1,
Figures S1B and S2). We found that irisin levels are present
at 3.6 ng/ml in sedentary individuals and are significantly
increased to 4.3 ng/ml in individuals undergoing aerobic inter-
val training (Figure 2C, Table 1).
DISCUSSION
We have developed here a quantitative, precise, and unbiased
assay for the detection of human irisin in plasma. This assay
definitively shows that human irisin circulates and has a very
similar or identical architecture to the mouse protein (Bostromc.
Table 1. Quantification of Irisin in Plasma from Human Subjects
Sedentary
N-terminal
peptide
(femtomoles)
Internal
(femtomoles)
Combined
average
(femtomoles) ng/ml
Subject 1 16.66 12.78 14.72 3.68
Subject 2 11.98 12.3 12.14 3.03
Subject 3 13.73 15.59 14.66 3.66
Subject 4 16.21 16.7 16.455 4.11
Average 14.65 14.34 14.49 3.62
Aerobic
N-terminal
peptide
(femtomoles)
Internal
(femtomoles)
Combined
average
(femtomoles) ng/ml
Subject 1 13.98 14.78 14.38 3.66
Subject 2 18.22 19.74 18.98 4.74
Subject 3 16.11 22.22 19.165 4.79
Subject 4 16.28 17.38 16.83 4.28
Subject 5 16.68 19.2 17.94 4.48
Subject 6 15.1 17.11 16.105 4.02
Average 16.06 18.41 17.23 4.33
Skyline software was used to quantify absolute amounts of irisin peptides
from the plasma of sedentary and aerobically trained subjects. The
25 kDa glycosylated bioactive form of irisin was used to calculate its
ng/ml concentrations in plasma.et al., 2012). Human irisin circulates at a level at or above the
levels observed for many other important biological hormones,
as shown in Figure 2D. It confirms earlier reports that have iden-
tified a unique peptide in human plasma by untargeted mass
spectrometry (Albrecht et al., 2015; Lee et al., 2014), but pro-
vides quantitation of the circulating levels of human irisin in an
unbiased and antibody-independent manner. Irisin concentra-
tions are present at 3.6 ng/ml in sedentary individuals and
are significantly increased to 4.3 ng/ml in individuals undergo-
ing aerobic interval training. We therefore also confirm our earlier
report of irisin being regulated by endurance exercise in humans
(Bostrom et al., 2012).
Several papers have called the start codon of the human
FNDC5 gene, which is an ATA, rather than the more common
ATG, a mutation. Indeed, these authors concluded that human
FNDC5 is a non-coding ‘‘pseudogene’’ or that ‘‘the human spe-
cies has an effective gene knockout of FNDC5’’ (Albrecht et al.,
2015; Raschke et al., 2013). This claim was based on a transfec-
tion assay expressing human FNDC5 from a CMV-promoter-
driven plasmid, which yielded protein levels lower than human
FNDC5 expressed with an ATG instead of an ATA from the
same plasmid. However, several lines of reasoning stand against
that claim. First, the high degree of conservation of the irisin
amino acid sequence across most mammalian species
(including humans) strongly argues against FNDC5 in humans
being a pseudogene. Second, the simple fact that Raschke
et al. detect human FNDC5 protein made from the ATA-FNDC5
sequence proves that human FNDC5 is not a pseudogene; these
are generally defined as genes that have lost their protein-coding
ability (Vanin, 1985). Third, their conclusion that low protein
production from CMV-promoter-driven plasmid expressed in
HEK293 cells translates to inefficient FNDC5 translation in vivo
is completely speculative, since this experiment did not considerCellendogenous regulation of human FNDC5 in its native state.
Indeed, non-canonical starts of translation are often indicative
of complex regulation of translation (Chang and Wang, 2004;
Starck et al., 2012). Fourth, as mentioned above, our detection
here of equal amounts of peptide 1 and 2 in human plasma
demonstrates that human irisin is, in fact, mainly translated
from its non-canonical start codon and not the further down-
stream ATG.
The earlier report (Albrecht et al., 2015) had several serious
methodological deficiencies. First, their failure to detect irisin in
human serum at 12 kDa by western blotting relied on deglyco-
sylation by only one enzyme, namely PNGase F; however, this
leads to only incomplete deglycosylation. PNGase F is an effec-
tive enzymatic method for removing almost all N-linked oligosac-
charides, but not other oligosaccharides. Hence, with PNGase F,
no visible band will appear at 12 kDa and the irisin signal will be
diluted across the lane, leading to apparent lower levels. In our
previously published method (Wrann et al., 2013), we used the
ProteinDeglycosylationMix fromNEB,whichcontains, inaddition
to PNGase F, O-glycosidase, neuraminidase, b1-4-galactosi-
dase, and b-N-acetylglucosaminidase; this leads to complete de-
glycosylationand theappearanceof12kDabands in recombinant
mammalian irisin and human plasma by immunoblot (Figure 1).
Second, these authors (Albrecht et al., 2015) used amethod of
protein mass spectrometry called ‘‘shotgun proteomics,’’ which
randomly samples peptides for detection from all the peptides
contained in the sample. While the method has the potential to
detect irisin, it would be suboptimal for detection because the
peptides of interest can be missed in complex samples due
to their low abundance. In these cases targeted proteomics is
required. This allows the mass spectrometer to focus on the
targeted peptides and ignore signal from co-eluting peptides.
AQUA-based quantification concomitantly with PRM produces
spectra that are highly specific because all potential product
ions of a peptide and elution profile confirm the identity of the
peptide.
Third, and perhaps most importantly, the authors report their
own detection limits for irisin at about 100 ng/ml. However,
many reports of human irisin fall below this level (Kraemer
et al., 2014; Kurdiova et al., 2014; Moraes et al., 2013; Wang
et al., 2015; Zhang et al., 2014). Hence it is rather surprising
that these authors concluded that human irisin did not exist or
was a ‘‘myth.’’
It is worth noting that limitations of own study include that the
AQUA heavy peptides were added to the irisin preparations after
the extraction of the proteins from the SDS-PAGE gel; we there-
fore cannot account for how much irisin protein was lost during
the sample preparation (albumin/IgG removal, deglycosylation,
and retrieval from the gel band, etc.); the numbers reported
here must therefore be considered a slight underestimation of
the irisin levels. In our experience, typical losses during sample
preparation range between 10%and 30%. In addition, this assay
is relatively costly and relies on available mass spectrometry
instrumentation and capabilities. However, while this assay is
relatively low throughput, it shouldprove useful for benchmarking
more high-throughput assays as they are developed. Taken
together, targetedmass spectrometry with the use of heavy irisin
AQUA peptides settles the existence, the overall architecture of
human irisin in the plasma, and its regulation by exercise.Metabolism 22, 734–740, October 6, 2015 ª2015 Elsevier Inc. 737
EXPERIMENTAL PROCEDURES
Aerobic Interval Training
Plasma samples were collected from young healthy participants (n = 6 males,
25 ± 5 years, BMI = 24.3 ± 2.5 kg/m2) following 12 weeks of high-intensity
aerobic training. Training consisted of 3 days/week of intervals on a cycle
ergometer (4 3 4 min > 90% peak aerobic capacity + 3 min rest) separated
by 2 days/week of walking on a treadmill (45 min at 70% peak aerobic capac-
ity). All training was supervised at the Dan Abraham Healthy Living Center at
the Mayo Clinic, Rochester. A separate sedentary group served as no-treat-
ment control (n = 4 males, 26 ± 3 years, BMI = 26.1 ± 3.4 kg/m2). Written
informed consent approved by the Mayo Clinic Institutional Review Board
was given by all participants before entering the study.
Plasma Collection and Purification
Participants consumed a weight-maintaining diet for 3 days and then were
admitted to the Clinical Research Unit at Mayo Clinic Hospital. The aerobic
training group did not exercise during the 3-day meal period. Participants
consumed a standardized evening meal and then remained fasted overnight.
Arterialized blood was collected at 7:00 a.m. into sodium heparin tubes from
a retrograde catheter in a dorsal hand vein (heated to 49C). Plasma was
separated by centrifugation and stored at80C until analysis. Human plasma
specimens (100 ml) were depleted of albumin and IgG using the ProteoExtract
kit (Millipore) and subsequently concentrated using 3 kDa molecular weight
cut-off spin-filter columns (Millipore). Deglycosylation of plasma was per-
formed using Protein Deglycosylation Mix (NEB) as per the manufacturer’s
denaturing protocol. Deglycosylated plasma samples were reduced with
10 mM DTT and alkylated with 50 mM iodoacetamide prior to being
resolved by SDS-PAGE using 4%–12% NuPAGE Bis-Tris precast gels (Life
Technologies).
Western Blotting
For western blotting analyses, 50 mg of protein was resolved for each plasma
sample by SDS-PAGE. Gels were transferred to 0.2-mm pore size Protran
(BA83) nitrocellulose membranes (Whatman) in 25 mM Tris, 200 mM glycine.
Membranes were blocked with 10% nonfat dry milk in PBS containing 0.1%
Tween (PBST) for 1 hr at room temperature. Membranes were then probed
with anti-FNDC5 (Irisin) rabbit polyclonal antibody (1:1,000) (IN102, Adipogen)
overnight at 4C, washed with PBST, and incubated with horseradish peroxi-
dase-conjugated secondary antibodies (1:3,000) (Sigma) followed by chemilu-
minescent (Perkin Elmer Life Sciences) detection. Recombinant mammalian
irisin was obtained from Ember Therapeutics.
In-Gel Digestion
For in-gel digestions, deglycosylated plasma samples (300 mg) were reduced
with 10 mM DTT and alkylated with 50 mM iodoacetamide prior to being
resolved by SDS-PAGE using 4%–12% NuPAGE Bis-Tris precast gels (Life
Technologies). Gels were Coomassie stained and fragments were excised
from the 10–15 kDa region. Gel pieces were destained and dehydrated with
100% acetonitrile, vacuumed dried, and resuspended with 50 mM ammo-
nium bicarbonate (Sigma-Aldrich), and 500 ng sequencing-grade trypsin
(Promega) was added for an overnight incubation at 37C (Shevchenko
et al., 1996). Digests were quenched after 12 hr with 5% formic acid and
de-salted using homemade C18 StageTips as previously described (Rap-
psilber et al., 2007). Peptides were eluted with 70% acetonitrile and 1% for-
mic acid, then dried using a speedvac and resuspended in 10 ml of 5% formic
acid and 4% acetonitrile containing the heavy valine-synthesized irisin pep-
tides (Table S1).
LC-MS/MS
Mass spectrometry data were collected using a Q Exactive or LTQ Orbitrap
Elite mass spectrometer (Thermo Fisher Scientific) coupled with a Famos
Autosampler (LC Packings) and an Accela 600 liquid chromatography (LC)
pump (Thermo Fisher Scientific). Peptides were separated onto a 100-mm
inner diameter microcapillary column packed with 0.5 cm of Magic C4
resin (5 mm, 100 A˚, Michrom Bioresources) followed by 20 cm of Accucore
C18 resin (1.6 mm, 150 A˚, Thermo Fisher Scientific). For each analysis, we
loaded 4 ml onto the column. Peptides were separated using a 50-min738 Cell Metabolism 22, 734–740, October 6, 2015 ª2015 Elsevier Ingradient of 8%–30% acetonitrile in 0.125% formic acid with a flow rate of
250 nl/min.
PRM Acquisition
PRM analyses were performed using a Q Exactive mass spectrometer
(Thermo Fisher Scientific) using the following parameters: a full MS scan
from 400 to 700 Thomson (Th) at an orbitrap resolution of 70,000 (at m/z
200), AGC target 53 106, and a 500msmaximum injection time. Full MS scans
were followed by 25–50 PRM scans at 35,000 resolution (at m/z 200) (AGC
target 5 3 106, 500 ms maximum injection time) as triggered by a scheduled
inclusion list (Table S2). The PRM method employed an isolation of target
ions by a 2 Th isolation window, fragmented with normalized collision energy
(NCE) of 25. MS/MS scans were acquired with a starting mass range of
100m/z and acquired as a profile spectrum data type. Precursor and fragment
ions were quantified using Skyline version 3.1 (MacLean et al., 2010).
Data-Dependent Acquisition
For data-dependent acquisitions using Q Exactive, the scan sequence
began with an Orbitrap MS1 spectrum with the following parameters:
resolution 70,000, scan range 400–1,400 Th, automatic gain control
(AGC) target of 5 3 106, maximum injection time of 250 ms, and centroid
spectrum data type. We selected the top 20 precursors for MS2 analysis,
which consisted of high-energy collision dissociation (HCD) with the
following parameters: resolution 17,500, AGC 1 3 105, maximum injection
time 60 ms, isolation window 2 Th, NCE 25, and acquired as a centroid
spectrum data type. The underfill ratio was set at 9%, which corresponds
to a 1.5 3 105 intensity threshold. In addition, unassigned and singly
charged species were excluded from MS2 analysis and dynamic exclusion
was set to automatic.
For data-dependent acquisitions using an LTQ Orbitrap Elite, the MS1
survey scan was performed in the orbitrap in the range of 300–1,500 Th at a
resolution of 3 3 104, followed by the selection of the ten most intense ions
(TOP10) for CID-MS2 fragmentation using a precursor isolation width window
of 2 Th. The AGC settings were 33 106 and 2.53 105 ions for survey and MS2
scans, respectively. Ions were selected for MS2 when their intensity reached
a threshold of 500 counts and an isotopic envelope was assigned. Maximum
ion accumulation times were set to 1,000 ms for survey MS scans and to
250 ms for MS2 scans. Singly charged ion species and ions for which a charge
state could not be determinedwere not subjected toMS2. Ionswithin a 10 ppm
m/z window around ions selected for MS2 were excluded from further selec-
tion for fragmentation for 120 s.
Peptide and Protein Identification
Following mass spectrometry data acquisition, Thermo Fisher RAW files
were converted into mzXML format and processed using a suite of software
tools developed in-house for analysis of proteomics datasets. All precursors
selected for MS/MS fragmentation were confirmed using algorithms to detect
and correct errors in monoisotopic peak assignment and refine precursor
ion mass measurements. All MS/MS spectra were then exported as individ-
ual DTA files and searched using the Sequest algorithm (Eng et al., 1994).
These spectra were searched against a database containing sequences of
all human proteins reported by Uniprot (Magrane and Consortium, 2011) in
both forward and reversed orientations. Common contaminating protein se-
quences (e.g., human keratins, porcine trypsin) were included as well. The
following parameters were selected to identify peptides from unenriched pep-
tide samples: 25 ppm precursor mass tolerance, 0.02 Da product ion mass
tolerance, no enzyme digestion, up to two tryptic missed cleavages, variable
modifications: oxidation of methionine (+15.994915) and deamidation of
asparagine (0.984016), fixed modifications: carbamidomethylation of cysteine
(+57.021464). The AScore algorithm was implemented to quantify the confi-
dence with which each deamidation modification could be assigned to a
particular residue in each peptide (Beausoleil et al., 2006). Peptides with
AScores above 13 were considered to be localized to a particular residue
(p < 0.05).
Statistical Analysis
Data analysis was performed using GraphPad Prism 6 software. Where appro-
priate, an unpaired, two-tailed Student’s t test was used. Significance wasc.
assigned to differences with a p value < 0.05. Pooled data are presented as
mean ± SEM.
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